Home | Meeting coverage | ASCO 2022

Highlighs in MBC: Discussions

ASCO 2022

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

CDK4/6i switch: who benefits from switching the CDK4/6...

MAINTAIN

ASCO 2022

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

What are the cosenquences of the new OS data for CDK4/6...

PALOMA-2

ASCO 2022

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

More data needed: Are the results clinical meaningful?...

TROPiCS-02

ASCO 2022

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

Paradigm shift in breast cancer: Where do we use the...

Destiny-Breast04

ASCO 2022

Hope Rugo, MD; Diana Lüftner, MD; Volkmar Müller, MD

Transatlantic differences in ADC side effects...

MBC treatment Perspectives: Discussion

ASCO 2022

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

How to determine progress of disease? How to proceed...

MAINTAIN

ASCO 2022

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

What clincial value has statistical signifcance? How...

TROPiCS-02

ASCO 2022

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

Determining HER2 receptor expression: How do we target...

Destiny-Breast04

ASCO 2022

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

Patients perspectives: ADCs - how do manage the new,...

Tropics02; Destiny-Breast04

ASCO 2022

J. Cortes, D. Lüftner, P. Fasching

ADCs & CDK4/6i - paradigm shifts and therapy switches...

Destiny-Breast04; U31402-A-J101; PALOMA-2; MAINTAIN

Breast cancer metastatic: 100 seconds ENG

ASCO 2022

Wolfgang Janni, MD

Oligometastasis: no advantage of additional...

NRG-BR002

ASCO 2022

Giuseppe Curigliano, MD

Revolution in the field of HR+ disease

Destiny-Breast04

ASCO 2022

Sara Tolaney, MD

T-DxD should be the new SoC for Her2low MBC patients

Destiny-Breast04

ASCO 2022

Sara Tolaney, MD

SG may be a good option for pre-treated HR+/Her2- pts

TROPiCS-02

ASCO 2022

Carmen Criscitiello, MD

SG is a new therapy option for HR+/HER2- MBC patients

Tropics02

ASCO 2022

Fatima Cardoso, MD

My ASCO22 highlights in metastatic breast cancer

Destiny-Breast04, Destiny-Breast03, TROPiCS-2, PALOMA-2, MAINTAIN, NRG-BR002

ASCO 2022

Nadia Harbeck, MD

Palbociclib - Overall survival data

PALOMA-2

ASCO 2022

Alessandra Gennari, MD

No changes in clinical practice after new CDK4/6i-data

PALOMA-2; MAINTAIN

ASCO 2022

Peter Fasching, MD

Combi SERD + Palbo reduces proliferation better than...

coopERA BC

ASCO 2022

Andreas Schneeweiss, MD

Good therapeutic option in HR+ HER2- mBC after failure...

Tropics02

ASCO 2022

Carmen Criscitiello, MD

Exciting and practice changing news for HR+/Her2low MBC...

Destiny-Breast04

ASCO 2022

Andreas Schneeweiss, MD

No effect for local treatment of metastasis

NRG-BR002

ASCO 2022

Karen Gelmon, MD

Endocrine therapy alone is important in treatment of...

ASTER

ASCO 2022

Gil Morgan, MD

Gamechanger in breast cancer

Destiny-Breast04

ASCO 2022

Nadia Harbeck, MD

Practice changing data

Destiny-Breast04

ASCO 2022

Andreas Schneeweiss, MD

Patritumab Deruxtecan: HER3-targeted ADC in HER3...

ASCO 2022

Elzbieta Senkus-Konefka, MD

First evidence on benefit of CDK4/6 inhibitors beyond...

MAINTAIN

ASCO 2022

Wolfgang Janni, MD

ADC: future therapeutic option in advanced HR+/HER2 BC

TROPiCS-02

ASCO 2022

Javier Cortes, MD

New agents for the clincial practice

DESTINY-Breast04; TROPiCS-02

ASCO 2022

Andreas Schneeweiss, MD

Improvment of PFS & OS with activated alteration...

FAKTION

ASCO 2022

Karen Gelmon, MD

Discontiunation of trial is disappointing despite...

NRG-BR002

ASCO 2022

Véronique Diéras, MD

Fascinating data of ADCs in breast cancer at ASCO22

Tropics02; Destiny-Breast04

ASCO 2022

Diana Lüftner, MD; Volkmar Müller, MD

Disappoiting final OS data and its implications for our...

PALOMA-2

ASCO 2022

Andreas Schneeweiss, MD

Possible explanations of the negative study

PALOMA-2

ASCO 2022

Carmen Criscitiello, MD

Combination of ctDNA and TKa assesment may improve...

BioItaLEE

ASCO 2022

Michael Untch, MD

Breakthrough news with antibody drug conjugate

DESTINY-Breast04; TROPiCS-02

ASCO 2022

Wolfgang Janni, MD

Option for overcoming endocrine resistance?

FAKTION

ASCO 2022

Andreas Schneeweiss, MD

Additional administration of ribociclib improves PFS...

MAINTAIN

ASCO 2022

Hope Rugo, MD

Exciting advances across a wide subset of breast...

TROPICS-02; Destiny-Breast04

ASCO 2022

Karen Gelmon, MD

New standard of care for HR+/Her2low patients

Destiny-Breast04

ASCO 2022

Elzbieta Senkus-Konefka, MD

New SoC for large subpopulation of breast cancer...

Destiny-Breast04

ASCO 2022

Giuseppe Curigliano, MD

Smart chemotherapy improves PFS

TROPiCS-02

ASCO 2022

Wolfgang Janni, MD

Benefit of CDK4/6 Switch after Progression

MAINTAIN

ASCO 2022

Barbara Pistilli, MD

Impressive and practice changing data of ADCs mark the...

Destiny-Breast 04; Tropics-02

ASCO 2022

Sara Tolaney, MD

Sacituzumab govitecan improves PCr in patients with...

NeoSTAR

Breast Cancer metastatic: 100 seconds Multi Language

ASCO 2022

Giuseppe Curigliano, MD

Il sacituzumab govitecan migliora il PFS nei tumori...

TROPiCS-02

ASCO 2022

Barbara Pistilli, MD

Les nouvelles données impressionnantes des ADC à l’ASCO...

Destiny-Breast 04; Tropics-02

ASCO 2022

Elzbieta Senkus-Konefka, MD

Nowy standard dla znaczącej subopulacji chorych na raka...

Destiny-Breast04

ASCO 2022

Carmen Criscitiello, MD

Novità entusiasmanti e practice changing per le...

Destiny-Breast04

ASCO 2022

Giuseppe Curigliano, MD

Una rivoluzione per il tumore mammario...

Destiny-Breast04

ASCO 2022

Carmen Criscitiello, MD

SG come nuova opzione di cura per le pazienti con...

Tropics02

ASCO 2022

Javier Cortes, MD

ADCs en cáncer de mama con receptores hormonales...

DESTINY-Breast04; TROPiCS-02

ASCO22

Michael Untch, MD

Noutăți inovatoare cu conjugatul de medicamente cu...

Destiny-Breast04, Tropics-02

ASCO 2022

Alessandra Gennari, MD

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

PALOMA-2; MAINTAIN

ASCO 2022

Elzbieta Senkus-Konefka, MD

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po...

MAINTAIN

ASCO 2022

Carmen Criscitiello, MD

La valutazione combinata di ctDNA e TKa può aiutare a...

BioItaLEE

ASCO 2022

Barbara Pistilli, MD

I nuovi impressionanti risultati degli ADC a l’ASCO...

Destiny-Breast 04; Tropics-02

Early breast Cancer: Discussions

ASCO 2022

N. Harbeck, K. Gelmon, C. Criscitiello, A. Schneeweiss, A. Gennari, M. Untch

CT benefit for elderly patients, if they are able to...

Aster 70s

ASCO 2022

N. Harbeck, A. Gennari, K. Gelmon, C. Criscitiello, M. Untch

Adding towards deescalation in luminal A EBC by...

LUMINA

ASCO 2022

A. Schneeweiss, N. Harbeck, K. Gelmon, C. Criscitiello, A. Schneeweiss, A. Gennari, M. Untch

Long term overall survival benefit of Denosumab in...

ABCSG-18

ASCO 2022

N. Harbeck, C. Criscitiello, K. Gelmon, A. Gennari, M. Untch

Neoadjuvant Pembro decreased RCB. SG - first promising...

KEYNOTE-522; NeoSTAR

ASCO 2022

C. Criscitiello, A. Schneeweiss, A. Gennari, K. Gelmon, M. Untch, N. Harbeck

Ovarian function suppression - it is here to stay!

ASTRRA

Breast cancer early: 100 seconds

ASCO 2022

Nadia Harbeck, MD

High concordance of local, central IHC and RT-PCR for...

ADAPT

ASCO 2022

Peter Fasching, MD

Combi SERD + Palbo redzuert proliferation better than...

coopERA BC

ASCO 2022

Fatima Cardoso, MD

My ASCO22 highlights in early breast cancer

iSPY-2, Keynote-522, ASTER-70s, ASTRRA, ABCSG-18

NSCLC metastatic: Discussion

ASCO 2022

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

Immunotherapy - Part 1

CheckMate 227; CheckMate 9LA; FDA pooled

ASCO 2022

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

Molecular landscape - Part 2

CHRYSALIS-2; CHRYSALIS

ASCO 2022

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

Molecular landscape - Part 1

KRYSTAL-1

ASCO 2022

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

Immunotherapy - Part 2

Lung-MAP

NSCLC metastatic: 100 Seconds ENG

ASCO 2022

Noemi Reguart, MD

New components and therapies for advanced NSCLC

CHRYSALIS-2; CHRYSALIS

ASCO 2022

Lizza Hendriks, MD

New treatment options for METexon 14 skipping:...

CHRYSALIS

ASCO 2022

Riyaz Shah, MD

Multiple aquired resistance mutations may drive disease...

CodeBreaK100

ASCO 2022

Nicolas Girard, MD

KRASG12C mutation: Adagrasib is comparabale to...

KRYSTAL-1

ASCO 2022

Sacha Rothschild, MD

COSMIC-021: Not practice-changing, but interesting...

COSMIC-021

ASCO 2022

Stephen Liu, MD

Amivantamab as a future option for METex14 patients?

CHRYSALIS

ASCO 2022

Nicolas Girard, MD

New option in patients harboring METex14 mutation

CHRYSALIS

ASCO 2022

Lizza Hendriks, MD

CLN-081 for patients with metastatic NSCLC and an...

ASCO 2022

Noemi Reguart, MD

In the second line: Options for Immunotherapy...

KRYSTAL-1

ASCO 2022

Riyaz Shah, MD

PD-L1 over 50%: Chemo-IO or IO?

FDA pooled analysis

ASCO 2022

Stephen Liu, MD

A chemo-free option in patients with EGFR-mutation

CHRYSALIS-2

ASCO 2022

Hossein Borghaei, MD

Strategies for PD-L1 > 50%

FDA pooled analysis

ASCO 2022

Lizza Hendriks, MD

Promising results for pre-treated patients with...

KRYSTAL-1

ASCO 2022

Riyaz Shah, MD

Is adagrasib an alternative to sotorasib?

KRYSTAL-1

ASCO 2022

Hossein Borghaei, MD

Options after progression to chemo/IO and for KRASG12C...

Lung-MAP; KRYSTAL-1

ASCO 2022

Sacha Rothschild, MD

Role of IO and chemo-IO in patients with PD-L1 > 50%

FDA pooled

ASCO 2022

Stephen, Liu, MD

CLN-081 is a promising new agent for EGFR exon 20...

ASCO 2022

Michael Thomas, MD

Bispecific Antibodies - the cMET field is moving

CHRYSALIS

NSCLC metastatic: 100 seconds Multi Language

ASCO 2022

Noemi Reguart, MD

Segunda Linea: opciones tras resistencia a...

KRYSTAL-1; Lung-MAP

ASCO 2022

Michael Thomas, MD

PD-L1 über 50 % - was tun?

ASCO 2022

Lizza Hendriks, MD

CLN-081 voor patienten met gemetastaseerd NSCLC en een...

ASCO 2022

Nicolas Girard, MD

Une nouvelle option, l’amivantamab, en situation de...

CHRYSALIS

ASCO 2022

Sacha Rothschild, MD

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >...

FDA pooled

ASCO 2022

Lizza Hendriks, MD

Veelbelovende resultaten voor voorbehandelde patienten...

KRYSTAL-1

ASCO 2022

Michael Thomas, MD

Bispezifische Antikörper - Neues von CHRYSALIS

ASCO 2022

Michael Thomas, MD

Was tun nach Versagen einer Chemoimmun-Therapie?

ASCO 2022

Noemi Reguart, MD

Nuevas terapias para el CPCNP avanzado

CHRYSALIS-2; CHRYSALIS

ASCO 2022

Lizza Hendriks, MD

Nieuwe behandelopties voor METexon 14 skipping:...

CHRYSALIS

ASCO 2022

Sacha Rothschild, MD

COSMIC-021: Nicht praxisverändernd, aber interessante...

COSMIC-021

ASCO 2022

Nicolas Girard, MD

L’adagrasib, inhibiteur de la mutation KRASG12C: une...

KRYSTAL-1

NSCLC early stages: Discussion

ASCO 2022

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

Neoadjuvant and adjuvant therapy - Part 2

NADIM II; CheckMate 816

ASCO 2022

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

Neoadjuvant and adjuvant therapy - Part 1

NADIM II; CheckMate 816

NSCLC early stages: 100 seconds

ASCO 2022

Gil Morgan, MD

NADIM-II strengthens the findings from CheckMate-816

NADIM-II

ASCO 2022

Martin Reck, MD

New treatment approaches in Stage III

KEYNOTE-799

ASCO 2022

Denis Moro-Sibilot, MD

A new option in neoadjuvant chemoimmunotherapy

NADIM II

ASCO 2022

Frank Griesinger, MD

CheckMate-816: Neoadjuvant therapy

CheckMate-816

ASCO 2022

Michael Thomas, MD

Perspectives on multimodality

NADIM II

NSCLC early stages: 100 seconds Multi Language

ASCO 2022

Martin Reck, MD

Neue Ansätze im Stadium III

KEYNOTE-799

ASCO 2022

Denis Moro-Sibilot, MD

Chimiothérapie néoadjuvante des stades III , vers un...

NADIM II

SCLC: 100 Seconds ENG

ASCO 2022

Denis Moro-Sibilot, MD

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is...

SKYSCRAPER-02

ASCO 2022

Frank Griesinger, MD

Immuncheckpoint-inhibitor therapy

ASCO 2022

Michael Thomas, MD

SKYSCRAPER-02: Subgroups could be important

SKYSCRAPER-02

ASCO 2022

Sacha Rothschild, MD

No benefit for tiragolumab / novel anti-PD-1 mAB...

SKYSCRAPER-02

SCLC: 100 seconds Multi Language

ASCO 2022

Denis Moro-Sibilot, MD

Le Tiragolumab n’apporte pas de bénéfice à la...

SKYSCRAPER-02

Prostate Cancer: Discussions

ASCO 2022

M.-O. Grimm, D. Murphy, A. Bjartell, E. Efstathiou, G. Morgan, N. Shore

mCRPC: LuPSMA - new treatment option in mCRPC

TheraP; VISION

ASCO 2022

A. Merseburger, A. Morgans, E. Efstahiou, D. Murphy, N. Shore, A. Bjartell

mHSPC: Transatlantic differences in genetic testing &...

ENZAMET; ARASENS

ASCO 2022

M.-O. Grimm, A. Bjartell, E. Efstahiou, G. Morgan, N. Shore

PARP inhibitors in mCRPC: Do we need more genetic...

Propel; MAGNITUDE; BRCAAWAY

Prostate Cancer: 100 seconds ENG

ASCO 2022

Alicia Morgans, MD

Arbiraterone + Olaparib: Is it synergistic?

BRCAAWAY

ASCO 2022

Gil Morgan, MD

TheraP shows no difference in overall survival between...

TheraP

ASCO 2022

Marc-Oliver Grimm, MD

Frequent imaging for early detection of metastases in...

ARAMIS

ASCO 2022

Anders Bjartell, MD

Surrogate endpoints in mHSPC

ASCO 2022

Yohann Loriot, MD

No big scoop, but encouraging results

ENZAMET

ASCO 2022

Axel Merseburger, MD

SHR3680 - do we need a new androgen receptor inhibitor

CHART

ASCO 2022

Ignacio Duran, MD

The highlights in GU cancers of ASCO22

The highlights in GU cancers of ASCO22

ASCO 2022

Alicia Morgans, MD

Further updates from the VISION trial

VISION

ASCO 2022

Anders Bjartell, MD

SUV mean at PET images as a prognostic tool for PSMA...

VISION

ASCO 2022

Axel Merseburger, MD

Lu-PSMA effective regardless of prior or concomitant...

VISION

ASCO 2022

Neal Shore, MD

GGT impacts PCa patients care

ASCO 2022

Alicia Morgans, MD

ADT alone is no longer standard of care

ENZAMET

ASCO 2022

Anders Bjartell, MD

3 year overall survival of TheraP study

TheraP

ASCO 2022

Gil Morgan, MD

The efficacy of doublets in mHSPC

ENZAMET

ASCO 2022

Axel Merseburger, MD

PFS good surrogate endpoint for overall survival

ASCO 2022

Neal Shore, MD

Ongoing trial invetiagting the impact of...

ASCO 2022

Axel Merseburger, MD

Lu-PSMA in the third line

TheraP

ASCO 2022

Neal Shore, MD

Value of triple-therapy - complimentary study to...

ARASEC

ASCO 2022

Declan Murphy, MD

LuPSMA & cabazitaxel are better than SoC alone

TheraP

ASCO 2022

Declan Murphy, MD

SUVmean is highly predictive of better PFS and OS

Vision

ASCO 2022

Anders Bjartell, MD

Phase 1 study on combining LuPSMA treatment with...

Prostate Cancer: 100 seconds Multi Language

ASCO 2022

Anders Bjartell, MD

Treårs överlevnadsresultat i TheraP studien.

TheraP

ASCO 2022

Ignacio Duran, MD

Lo mas destacado en tumores GU en ASCO 2022

ASCO 2022

Anders Bjartell, MD

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas...

ASCO 2022

Anders Bjartell, MD

Tidigare endpoints I mHSPC studier

ASCO 2022

Anders Bjartell, MD

Kvantifiering av PMSA PET upptaget som prognostisk...

VISION

ASCO 2022

Yohann Loriot, MD

Pas de nouvelles sensationnelles mais des données...

Kidney Cancer: Discussion

ASCO 2022

Philipp Iavnyi, MD; Laura-Maria Krabbe, MD

Combination Therapy is State of the Art in Metastatic...

CLEAR Study; KEYNOTE-426; CheckMate (CM) 214; CheckMate 9ER

ASCO 2022

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

EVEREST: Inisghts from the negative trial

EVEREST

ASCO 2022

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

What are the consequences for future trial design?

CheckMate9ER

ASCO 2022

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

The relevance of quality of life in kidney cancer!

CheckMate214

Kidney Cancer: 100 seconds ENG

ASCO 2022

Ignacio Duran, MD

The highlights in GU cancers of ASCO22

The highlights in GU cancers of ASCO22

ASCO 2022

Philipp Ivanyi, MD

Importance of health related quality of life

ASCO 2022

Hans Hammers, MD

Clear evidence for durable benefit for patients with...

LITESPARK-004

ASCO 2022

Hans Hammers, MD

PSMA-PET may improve imaging of clear cell RCC

ASCO 2022

Axel Merseburger, MD

Belzutifann shows good tumor activity in renal cancer

LITESPARK-004

ASCO 2022

Philipp Ivanyi, MD

Depth of remission in firstline

CheckMate 9ER

ASCO 2022

Hans Hammers, MD

QoL & DepOR correlate with clinical outcomes - reminder...

CheckMate 9ER; CheckMate 214

ASCO 2022

Hans Hammers, MD

Should Everolimus be revisited for high-risk patients?

EVEREST

ASCO 2022

Tom Powles, MD

Should we be looking at Everolimus in the future?

EVEREST

ASCO 2022

Axel Merseburger, MD

Combi Axi + Pembro also successful with good risk...

KEYNOTE-426

Kidney Cancer: 100 seconds - Multi Language

ASCO 2022

Yohann Loriot, MD

Pas de nouvelles sensationnelles mais des données...

ASCO 2022

Ignacio Duran, MD

Lo mas destacado en tumores GU en ASCO 2022

Bladder Cancer: Discussions

ASCO 2022

L.-M. Krabbe, M.-O. Grimm, J. Bellmunt, Y. Loriot, T. Powles

The role of systemic treatment in the pre-operative...

AURA; SAKK 06/17; JAVELIN

ASCO 2022

Laura-Maria Krabbe, MD; Marc-Oliver Grimm, MD

New data on TKi utilization in bladder cancer

COSMIC-021

ASCO 2022

L.-M. Krabbe, M.-O. Grimm, J. Bellmunt, Y. Loriot, T. Powles

ADCs: do we enter a new era of therapy for urothelial...

EV-103; RC-48

Bladder Cancer: 100 seconds ENG

ASCO 2022

Neal Shore, MD

Investigating sasanlimab in BCG-unresponsive NMIBC

CREST cohort B

ASCO 2022

Tom Powles, MD

Exciting future for ADCs

EV-301; RC48-ADC

ASCO 2022

Petros Grivas, MD

My highlights in localized urothelial cancer

QUILT 3.032; SWOG S1314

ASCO 2022

Tom Powles, MD

The end of of VEGF-targeted therapy in urothelial...

COSMIC-021; ATLANTIS

ASCO 2022

Laura-Maria Krabbe, MD

Perioperative immuno-chemotherapy in MIBC

SAKK 06/17

ASCO 2022

Philipp Ivanyi, MD

BCG failure

ASCO 2022

Philipp Ivanyi, MD; Peter Goebell, MD

ADCs: News from ASCO 2022

ASCO 2022

Petros Grivas, MD

My highlights of metastasized urothelial cancer

ATLANTIS; MAIN_CAV

ASCO 2022

Yohann Loriot, MD

No big scoop, but encouraging results

ENZAMET

ASCO 2022

Ignacio Duran, MD

The highlights in GU cancers of ASCO22

The highlights in GU cancers of ASCO22

ASCO 2022

Philipp Ivanyi, MD

Maintenance concepts

Bladder Cancer: 100 seconds - Multi Language

ASCO 2022

Petros Grivas, MD

Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το...

ASCO 2022

Ignacio Duran, MD

Lo mas destacado en tumores GU en ASCO 2022

Varia

ASCO 2022

Philipp Ivanyi, MD

News from Sarcoma

ASCO 2022

Axel Merseburger, MD

Few testicular tumors after 5 years

ASCO 2022

Philipp Ivanyi, MD

Precision oncology - NTRK worth to search the patients

ASCO22

C. Moisidis-Tesch, MD; L.P. Shulman, MD

Opportunities & challenges of cancer genetics

ASCO 2022

Philipp Ivanyi

Systemic therapy

ASCO 2022

Philipp Ivanyi, MD

Radiotherapy as a new standard for cisplatin ineligible...